Get the Stockscreener App
2.91
0.69%
0.02
Prime Medicine Inc stock is traded at $2.91, with a volume of 762.72K.
It is up +0.69% in the last 24 hours and up +0.34% over the past month.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
See More
Previous Close:
$2.89
Open:
$2.92
24h Volume:
762.72K
Relative Volume:
0.69
Market Cap:
$381.68M
Revenue:
-
Net Income/Loss:
$-217.44M
P/E Ratio:
-1.341
EPS:
-2.17
Net Cash Flow:
$-205.20M
1W Performance:
+7.78%
1M Performance:
+0.34%
6M Performance:
-45.15%
1Y Performance:
-55.23%
1-Day Range:
$2.83
$3.03
1-Week Range:
$2.75
$3.03
52-Week Range:
$2.56
$9.77
Prime Medicine Inc Stock (PRME) Company Profile
Name
Prime Medicine Inc
Sector
Industry
Phone
617-465-0013
Address
60 FIRST ST., CAMBRIDGE
Compare PRME with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRME
Prime Medicine Inc
|
2.91 | 381.68M | 0 | -217.44M | -205.20M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Prime Medicine Inc Stock (PRME) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Initiated | JMP Securities | Mkt Outperform |
| May-20-24 | Initiated | H.C. Wainwright | Buy |
| May-16-24 | Upgrade | Citigroup | Neutral → Buy |
| Apr-22-24 | Initiated | Chardan Capital Markets | Buy |
| Apr-08-24 | Initiated | TD Cowen | Buy |
| Apr-03-24 | Initiated | Wedbush | Outperform |
| Jan-16-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Initiated | Citigroup | Neutral |
| Oct-09-23 | Initiated | BMO Capital Markets | Outperform |
| Jul-31-23 | Initiated | Guggenheim | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Nov-14-22 | Initiated | Goldman | Neutral |
| Nov-14-22 | Initiated | JP Morgan | Overweight |
| Nov-14-22 | Initiated | Jefferies | Buy |
| Nov-14-22 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prime Medicine Inc Stock (PRME) Latest News
Barclays PLC Increases Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to Sell - MarketBeat
StockNews.com Upgrades Prime Medicine (NYSE:PRME) to “Sell” - Defense World
Prime Medicine Advances Gene Editing and Trials - TipRanks
Jane Street Group LLC Trims Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Average Price Target from Analysts - Defense World
Prime Medicine to Present at 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
Prime Medicine (NYSE:PRME) Rating Increased to Sell at StockNews.com - Defense World
Prime Medicine (NYSE:PRME) Upgraded at StockNews.com - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Given Average Rating of "Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $5.26 Million Stock Position in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Barclays PLC Boosts Stake in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Is Prime Medicine (PRME) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Why Prime Medicine (PRME) Is One of the Best Biotech Penny Stocks to Invest in Now? - Insider Monkey
State Street Corp Buys 43,086 Shares of Prime Medicine, Inc. (NYSE:PRME) - Defense World
Top 11 CRISPR Stocks to Invest In - Insider Monkey
12 Best Biotech Penny Stocks To Invest In Now - Insider Monkey
Prime Medicine, Inc. (PRME): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Prime Medicine (NYSE:PRME) Upgraded to "Sell" at StockNews.com - MarketBeat
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans? - Simply Wall St
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal 2025 - Investing.com
When Would Be The Best Time To Buy Prime Medicine Inc (NASDAQ: PRME) Stock? - Stocks Register
Prime Medicine, Inc. (NYSE:PRME) Receives $12.67 Consensus Price Target from Analysts - Defense World
Prime Medicine Files for Resale of 11 Million Shares - Marketscreener.com
Prime Medicine initiated with an Outperform at JMP Securities - MSN
Prime Medicine (NYSE:PRME) Stock Rating Upgraded by Citizens Jmp - MarketBeat
Prime Medicine, Inc. (NYSE:PRME) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Fmr LLC Sells 184,541 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Prime Medicine's SWOT analysis: gene editing firm's stock faces pivotal year - Investing.com Canada
Prime Medicine stock a top pick for gene editing, says JMP Securities - Investing.com Canada
Prime Medicine (NYSE:PRME) Now Covered by Analysts at JMP Securities - MarketBeat
Intech Investment Management LLC Acquires Shares of 14,102 Prime Medicine, Inc. (NYSE:PRME) - Defense World
Prime Medicine (NYSE:PRME) Earns Buy Rating from Guggenheim - Defense World
Vestal Point Capital LP Purchases 620,000 Shares of Prime Medicine, Inc. (NYSE:PRME) - MarketBeat
Comparing Century Therapeutics (NASDAQ:IPSC) & Prime Medicine (NYSE:PRME) - Defense World
Prime Medicine's Bristol Myers Partnership Boosts Outlook For Gene Editing Therapies - Seeking Alpha
Oppenheimer & Co. Inc. Has $69,000 Stock Holdings in Prime Medicine, Inc. (NYSE:PRME) - Defense World
GSA Capital Partners LLP Invests $383,000 in Prime Medicine, Inc. (NYSE:PRME) - Defense World
Brokerages Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $13.25 - Defense World
Prime Medicine Inc Stock (PRME) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):